Case: Whistleblowers accused a national lab company of falsely billing Medicare and Medicaid for high complexity quantitative urine drug tests under CPT code G0431 at up to $476 per test. According to … [Read more...]
FALSE CLAIMS
Federal Court Dismisses Whistleblowers’ Urine Drug Test False Billing Claim
January 2, 2020
Sales & Marketing: The Perils of Restructuring Sales Commissions for EKRA
January 2, 2020
For many years, it was fairly common practice for labs to pay their sales representatives variable compensation based on the volume and value of the tests they generated. But those arrangements became … [Read more...]
DIAGNOSTIC DEALS
Diagnostic Deals: Illumina/PacBio Merger Derails & Qiagen Takes Itself Out of Play
December 31, 2019
As 2019 came to a close, the biggest story in DX deal making was the pair of anticipated M&A deals that suddenly seem unlikely to happen. As a result, two major genetic testing companies will … [Read more...]
DIAGNOSTIC DEALS
Diagnostic Deals: The Fate of Illumina-PacBio Merger Hangs in the Balance
November 30, 2019
Will they or won’t they? The suspense continues over whether Illumina’s proposed rescue of Pacific Biosciences will actually close. The $1.2 billion cash merger, which was originally expected to close … [Read more...]
Marketing Pitfalls to Avoid: Deceptive Advertising—the Other Kind of “False Claims”
November 28, 2019
We all know that marketing activity is a breeding ground for potential lab liability. But while most labs are sensitive to the risks posed by the Antikickback Statute, Stark Law and False Claims Act, … [Read more...]
DIAGNOSTIC DEALS
Diagnostic Deals: A roundup of the key mergers, acquisitions, alliances, licenses and other strategic transactions from the past month
October 31, 2019
Although briskness in alliances partially offset sluggishness in M&A, October was far less dynamic than September for strategic deal making within the diagnostics sector. Here’s an overview of the … [Read more...]
FALSE CLAIMS
Federal Court Dismisses Urine Drug Test False Billing Claim
October 30, 2019
Case: Whistleblowers accused a national lab company of falsely billing Medicare and Medicaid for high complexity quantitative urine drug tests under CPT code G0431 at up to $476 per test. According to … [Read more...]
Compliance Perspectives: California Case Illustrates Lab’s Liability Risks for “Causing” MDs to Submit False Claims
October 28, 2019
False Claims Act (FCA), 101: Knowingly submitting a false claim to Medicare or another federally funded health care program is a violation. But what’s lesser known is that your lab can also be liable … [Read more...]
MARKETING
LabCorp Must Go to Trial to Defend against Deceptive Trade Practices Charges
October 24, 2019
Case: Fourteen patients sued LabCorp for allegedly overcharging them for lab tests. In March 2018, a North Carolina federal court tossed their class action ruling that the patients didn’t have a valid … [Read more...]
DIAGNOSTIC DEALS
Diagnostic Deals: A Roundup of the Key Mergers, Acquisitions, Alliances, Licenses and Other Strategic Transactions From the Past Month
September 30, 2019
After a brief summer lull, strategic deal making ramped up in September, especially in alliance making where volume nearly doubled last month’s levels. Here’s an overview of the long-term trends and … [Read more...]
